Terry Gregg, CEO, Dexcom, introduces himself and reveals why he is so passionate about helping people manage their diabetes sharing the fact that, through the new CGM technology, type 1 women who had previously been told they couldn’t have children, can now do so. More videos with Terry Gregg: Increases …

Terry Gregg, CEO, Dexcom, talks about some of the new technological breakthroughs his company is working on especially developing an artificial pancreas. Recent trials, of which Dexcom is involved in about 18, have dramatically increased the accuracy and effective functioning of some of these devices. He also discusses his interest …

Terry Gregg, CEO, Dexcom, talks about the recent FDA approval for using CGM devices in children as young as 2 years old and what this means for improvement in care for young type 1 diabetes patients. He also explains how Dexcom and Joslin are working together to develop more effective …

Terry Gregg, CEO, Dexcom, talks about the latest advance in continuous glucose monitoring technology in terms of sharing data via mobiles. With other new systems being developed, this could make it possible for parents to monitor their child’s blood sugars from anywhere including if the child was on a sleepover …

Terry Gregg, CEO, Dexcom, talks about how blood glucose monitoring in cars and getting updates while driving might not be a good idea but the potential prevention of traffic accidents is definitely something to look at….

Terry Gregg, CEO, Dexcom, talks about the reduction in hypo’s with better monitoring technology. This can also result in significant cost savings and Dexcom will hopefully be starting a study later this year examining the cost components of their products, and how to ensure that they are “part of the …

Terry Gregg, CEO, Dexcom, reviews some of the data that he has seen on the healthcare cost savings that continuous glucose monitoring technology can bring. Much of this comes from preventing hypoglycemic episodes that can result in an average hospital stay bill of around $17.000. But he also mentions that …

Terry Gregg, CEO, Dexcom, answers Steve’s questions about using CGM technology to help type 2 diabetes patients learn about blood sugar control. He reveals that he frequently talks about the greater role in behavior modification that CGM could play in helping not only those diagnosed with diabetes but perhaps even …

Terry Gregg, CEO, Dexcom, discusses the current landscape of reimbursement for CGM technology. Although insurance companies were initially slow to catch on for approving CGM devices for type 1’s, there has been a shift and approvals seem to be improving. He is also sees the overall market increasing as more …

Terry Gregg, CEO, Dexcom, shares his thoughts on a “cure” for diabetes, commenting that 20 years ago, he was told it would happen in 5-7 years. At this time he believes it is still a way off and that, “Realistically, we’ll proobably find a way to prevent it before we …